Eric Lefkofsky is a Chicago, Illinois, businessman who has co-founded multiple technology firms. Among these are InnerWorkings, Echo Global Logistics, MediaBank, and most famously Groupon. He has been a leader at these companies, including being the chief executive officer and chairman of the board. His latest company, Tempus, Inc. is bringing cutting-edge technology to the field of healthcare.
Tempus is a company that helps physicians deliver personalized care to cancer patients. His company built a library filled with data such as molecular data, clinical data, doctor’s notes, and genomic sequencing data. Machine learning and analytics sort this data and come up with relevant insights. Eric Lefkofsky says the goal is to help physicians develop individualized treatment plans that lead to better patient outcomes when diagnosed with this deadly disease.
He has partnered with many hospitals and universities around the nation. One of these is LSU Health Shreveport’s Feist-Weiller Cancer Center. This center is led by Maria-Magdalena Georgescu, M.D., Ph.D. She partnered with Tempus so that she could better research glioblastoma, a common and very deadly form of brain cancer. To date, people with this type of cancer face grim prospects because it grows too fast to be effectively targeted and treated.
Eric Lefkofsky says that the digital tools and analytics that his company provides to Feist-Weiller Cancer Center will help them better understand how their patient’s profiles, using their genetic information, will respond to various treatment options. They will be able to see what treatments can shrink or eliminate these types of tumors and lead to better patient outcomes.
Along with his long-time business partner, Eric Lefkofsky established Tempus in 2015. He says that he saw a need for much better technology when it comes to cancer care and decided he had the skills to fill it. He had gone along with a family member to their appointments to treat their cancer. He saw that physicians didn’t have access to the data that would help them better help their patients beat cancer. He put together a team of experts who built a platform that is now used for 25% of cancer patients in America.